Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Adriana Blancafort"'
Autor:
Adriana Blancafort, Ariadna Giró-Perafita, Glòria Oliveras, Sònia Palomeras, Carlos Turrado, Òscar Campuzano, Dolors Carrión-Salip, Anna Massaguer, Ramon Brugada, Marta Palafox, Jorge Gómez-Miragaya, Eva González-Suárez, Teresa Puig
Publikováno v:
PLoS ONE, Vol 10, Iss 6, p e0131241 (2015)
Blocking the enzyme Fatty Acid Synthase (FASN) leads to apoptosis of HER2-positive breast carcinoma cells. The hypothesis is that blocking FASN, in combination with anti-HER2 signaling agents, would be an effective antitumor strategy in preclinical H
Externí odkaz:
https://doaj.org/article/d0946f7276224e738d25e57de6ec46aa
Autor:
Teresa Puig, Alana L. Welm, Ariadna Sarrats, Ferran Pérez-Bueno, Glòria Oliveras, Gemma Viñas, Adriana Blancafort, David H. Lum, Sònia Palomeras, Ariadna Giró-Perafita
(A) 231 and 231DXR and (B) HCC and HCCDXR cells were treated with increasing concentrations of doxorubicin (50 - 350 nM) for 48h. Experiments were performed three times in triplicate. Results shown are mean {plus minus} SEM. *(p < 0.05), **(p < 0.01)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a0dc4a12d2701027c6a56bd1d40df5d
https://doi.org/10.1158/1078-0432.22462608
https://doi.org/10.1158/1078-0432.22462608
Autor:
Teresa Puig, Alana L. Welm, Ariadna Sarrats, Ferran Pérez-Bueno, Glòria Oliveras, Gemma Viñas, Adriana Blancafort, David H. Lum, Sònia Palomeras, Ariadna Giró-Perafita
cells (A) 231 and 231DXR and (B) HCC and HCCDXR cells were treated with increasing concentrations of cetuximab (0,5 - 4 µM), C75 (20 - 60 µM) or EGCG ( 25 - 150 µM) for 4 days. Results are expressed as mean {plus minus} SEM. Experiments were perfo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d1b348f65d50d103597c45b45fc82a0
https://doi.org/10.1158/1078-0432.22462596
https://doi.org/10.1158/1078-0432.22462596
Autor:
Teresa Puig, Alana L. Welm, Ariadna Sarrats, Ferran Pérez-Bueno, Glòria Oliveras, Gemma Viñas, Adriana Blancafort, David H. Lum, Sònia Palomeras, Ariadna Giró-Perafita
(A) 231 and 231DXR and (B) HCC and HCCDXR cells were treated with doxorubicin (50-100-150nM) and C75 (20µM for HCC, HCCDXR; 40µM for 231, 231DXR) or the combination for 48h. (C) 231 and 231DXR and (D) HCC and HCCDXR cells were treated with doxorubi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::443258cd2e2ece25708066dba734bd8f
https://doi.org/10.1158/1078-0432.22462599
https://doi.org/10.1158/1078-0432.22462599
Autor:
Teresa Puig, Alana L. Welm, Ariadna Sarrats, Ferran Pérez-Bueno, Glòria Oliveras, Gemma Viñas, Adriana Blancafort, David H. Lum, Sònia Palomeras, Ariadna Giró-Perafita
Purpose: Triple-negative breast cancer (TNBC) lacks an approved targeted therapy. Despite initial good response to chemotherapy, 30% of the patients relapse within 5 years after treatment. EGFR overexpression is a common marker in TNBC, and its expre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f535db6bd8c240075c66dde3cf919cf
https://doi.org/10.1158/1078-0432.c.6525147.v1
https://doi.org/10.1158/1078-0432.c.6525147.v1
Autor:
Teresa Puig, Alana L. Welm, Ariadna Sarrats, Ferran Pérez-Bueno, Glòria Oliveras, Gemma Viñas, Adriana Blancafort, David H. Lum, Sònia Palomeras, Ariadna Giró-Perafita
(A) Mice bearing 231 and (B) 231DXR xenografts were treated with saline (Control), EGCG (30mg/Kg, 3 days a week), cetuximab (0.5mg/mice 1 day a week) or the combination (EGCG plus cetuximab) for 12 days. (C) Mice bearing HCC and (D) HCCDXR xenografts
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::766d33ef3b26308bb1bff159b038f209
https://doi.org/10.1158/1078-0432.22462593
https://doi.org/10.1158/1078-0432.22462593
Autor:
Teresa Puig, Alana L. Welm, Ariadna Sarrats, Ferran Pérez-Bueno, Glòria Oliveras, Gemma Viñas, Adriana Blancafort, David H. Lum, Sònia Palomeras, Ariadna Giró-Perafita
(A) 231 and 231DXR and (B) HCC and HCCDXR. mRNA levels were obtained by Real-Time PCR and normalized against the β-actin gene. Results shown are mean {plus minus} SEM from 3 independent experiments.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1df61bbda18e92307485007b2fc5f75
https://doi.org/10.1158/1078-0432.22462605
https://doi.org/10.1158/1078-0432.22462605
Autor:
Teresa Puig, Alana L. Welm, Ariadna Sarrats, Ferran Pérez-Bueno, Glòria Oliveras, Gemma Viñas, Adriana Blancafort, David H. Lum, Sònia Palomeras, Ariadna Giró-Perafita
TNBC Patients demographics and clinical characteristics (n=26).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1dbb0ffcf005f32808d581168c66cdb5
https://doi.org/10.1158/1078-0432.22462590
https://doi.org/10.1158/1078-0432.22462590
Autor:
Teresa Puig, Alana L. Welm, Ariadna Sarrats, Ferran Pérez-Bueno, Glòria Oliveras, Gemma Viñas, Adriana Blancafort, David H. Lum, Sònia Palomeras, Ariadna Giró-Perafita
(A) 231 and 231DXR cells were treated with increasing concentrations of EGCG ( 100 - 200 µM) or C75 (30 - 90 µM) for 48h. (B) HCC and HCCDXR cells were treated with increasing concentrations of EGCG ( 100 - 250 µM) or C75 (20 - 60 µM) for 48h. Re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60a430c4f2e8c66eb0c0665df35775cc
https://doi.org/10.1158/1078-0432.22462602.v1
https://doi.org/10.1158/1078-0432.22462602.v1
Autor:
Lidia Feliu, Cristina Rosés, Adriana Blancafort, Teresa Puig, Daniel Carbajo, Miriam Royo, Anna D. Cirac, Glòria Oliveras, Fernando Albericio, Eduard Bardají, Josep Farrera-Sinfreu, Marta Planas, Glòria Sanclimens
Publikováno v:
Tetrahedron. 68:4406-4412
In this study, we combined a cell-penetrating γ-peptide, PEG-1, with antimicrobial undecapeptides in order to provide compounds with anticancer properties against MDA-MB-231 human breast cancer cells. We demonstrated that the conjugates were more cy